{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T22:52:56Z","timestamp":1775775176236,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.toxlet.2018.10.009","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T14:05:37Z","timestamp":1539180337000},"page":"145-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The hepatotoxic potential of protein kinase inhibitors predicted with Random Forest and Artificial Neural Networks"],"prefix":"10.1016","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-326X","authenticated-orcid":false,"given":"Verena","family":"Sch\u00f6ning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Drewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2018.10.009_bib0005","series-title":"Manual-Setting Up, Using, And Understanding Random Forests V4.0","first-page":"1","author":"Breimann","year":"2003"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1613\/jair.953","article-title":"SMOTE: synthetic minority over-sampling technique","volume":"16","author":"Chawla","year":"2002","journal-title":"J. Artif. Intell. Res."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0015","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0020","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.815","article-title":"Kinase inhibitors: the reality behind the success","volume":"102","author":"Jeon","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.currproblcancer.2013.06.001","article-title":"United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies","volume":"37","author":"Jeong","year":"2013","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jat.3551","article-title":"Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines","volume":"38","author":"Mingard","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0050","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/wcms.1183","article-title":"Machine learning methods in chemoinformatics","volume":"4","author":"Mitchell","year":"2014","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0055","first-page":"74","article-title":"A practical overview of quantitative structure-activity relationship","volume":"8","author":"Nantasenamat","year":"2009","journal-title":"EXCLI J."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0060","series-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","author":"National Cancer Institute","year":"2006"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fphar.2017.00367","article-title":"Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis","volume":"8","author":"Paech","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.toxlet.2018.10.009_bib0070","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s40264-014-0185-4","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/toxsci\/kfx187","article-title":"Editor\u2019s highlight: identification of any structure-specific hepatotoxic potential of different pyrrolizidine alkaloids using Random Forests and Artificial Neural Networks","volume":"160","author":"Sch\u00f6ning","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0085","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","volume":"88","author":"Takeda","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0110","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/jcc.21707","article-title":"PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints","volume":"32","author":"Yap","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0115","series-title":"Descriptors","author":"Yap","year":"2014"},{"key":"10.1016\/j.toxlet.2018.10.009_bib0120","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.113.056267","article-title":"High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2018.10.009_bib0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/ci500715e","article-title":"Recursive random forests enable better predictive performance and model interpretation than variable selection by LASSO","volume":"55","author":"Zhu","year":"2015","journal-title":"J. Chem. Inf. Model."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427418319921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427418319921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T13:09:02Z","timestamp":1540818542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427418319921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":25,"alternative-id":["S0378427418319921"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2018.10.009","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The hepatotoxic potential of protein kinase inhibitors predicted with Random Forest and Artificial Neural Networks","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2018.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}